Headlines about Pacira Pharmaceuticals (NASDAQ:PCRX) have been trending somewhat positive on Saturday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pacira Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.137480538605 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s analysis:
- Pacira Pharmaceuticals, Inc. (PCRX) CAO Sells $127,191.75 in Stock (americanbankingnews.com)
- Pacira Pharmaceuticals, Inc. (PCRX) CEO Sells $1,050,547.45 in Stock (americanbankingnews.com)
- Pacira Pharmaceuticals, Inc. (PCRX) registers a price change of 1.10% while Benitec Biopharma Limited (BNTC … – Stocks Gallery (stocksgallery.com)
- Changes in Signals Identified: Premier, Inc. (PINC), Pacira Pharmaceuticals, Inc. (PCRX) – AllStockNews (allstocknews.com)
- Pacira Pharmaceuticals (PCRX) Presents At Wedbush PacGrow Healthcare Conference – Slideshow (seekingalpha.com)
Shares of Pacira Pharmaceuticals (PCRX) opened at 35.80 on Friday. Pacira Pharmaceuticals has a 12-month low of $29.95 and a 12-month high of $58.95. The company’s market cap is $1.44 billion. The stock’s 50 day moving average price is $43.09 and its 200 day moving average price is $45.24.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.06. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The firm had revenue of $70.90 million during the quarter, compared to the consensus estimate of $73.37 million. During the same period in the prior year, the company posted $0.21 EPS. The firm’s revenue was up 1.9% on a year-over-year basis. On average, analysts forecast that Pacira Pharmaceuticals will post ($0.12) EPS for the current year.
PCRX has been the subject of a number of research reports. Mizuho reissued a “buy” rating and set a $54.00 target price on shares of Pacira Pharmaceuticals in a research note on Wednesday, July 26th. Royal Bank Of Canada set a $58.00 price objective on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 15th. ValuEngine cut Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. BidaskClub cut Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Finally, Wedbush restated an “outperform” rating and issued a $87.00 price target on shares of Pacira Pharmaceuticals in a research report on Wednesday, June 21st. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $54.50.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Pacira Pharmaceuticals (NASDAQ:PCRX) Stock Price” was reported by BNB Daily and is owned by of BNB Daily. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-pacira-pharmaceuticals-nasdaqpcrx-share-price-updated-updated.html.
In other Pacira Pharmaceuticals news, SVP Scott Braunstein sold 768 shares of Pacira Pharmaceuticals stock in a transaction on Monday, June 5th. The stock was sold at an average price of $43.32, for a total value of $33,269.76. Following the completion of the sale, the senior vice president now owns 9,982 shares of the company’s stock, valued at approximately $432,420.24. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Lauren Bullaro Riker sold 601 shares of Pacira Pharmaceuticals stock in a transaction on Monday, June 5th. The stock was sold at an average price of $43.32, for a total value of $26,035.32. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,869 shares of company stock valued at $1,590,276. 6.60% of the stock is owned by corporate insiders.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.